Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Inyta

- PMLiVE

Easier access to medicines in the UK?

Cutting through the NICE value-based assessment consultation to find out what’s at stake

- PMLiVE

NICE backs Celgene’s Revlimid in bone marrow disorder

Recommends that drug can be used on NHS to treat myelodysplastic syndromes

- PMLiVE

NICE backs Gilead’s Sovaldi in hepatitis C

But health watchdog denies earlier use of Janssen’s Zytiga

- PMLiVE

US panel backs pneumococcal vaccines for seniors

Vaccines to be provided by Merck & Co and Pfizer

- PMLiVE

Pfizer to work with genetics firm on bowel disease

Agrees deal with 23andMe to research ulcerative colitis and Crohn’s disease

National Institute for Health and Care Excellence NICE logo

Public advises NICE on value of care

Citizens Council publishes report on the way health and social care resources are allocated in the UK

- PMLiVE

Pfizer closes on $1bn label expansion for Prevenar

EMA begins review of the pneumococcal vaccine

- PMLiVE

Roche blasts UK’s ‘broken’ HTA system as Kadcyla rejected

But NICE says it is 'very disappointed' with the company's pricing policy

- PMLiVE

Pfizer’s arthritis drug Enbrel widens its European licence

Gains new indication for early-stage inflammatory joint disease

- PMLiVE

NICE set to block post-Velcade use of Revlimid

Watchdog's new draft guidance does not recommend Celgene blood cancer drug

- PMLiVE

Pfizer acquires Baxter Men C and encephalitis vaccines for $635m

Snaps up marketed vaccines and part of Baxter's Austrian manufacturing plant

- PMLiVE

European licence for BMS/Pfizer’s Eliquis in DVT and PE

Anticoagulant catches up with Bayer's Xarelto and Boehringer's Pradaxa

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links